Best Infectious Diseases Companies in Ontario, Canada
The 31 best Infectious Diseases companies in Ontario, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Xagenic.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Ontario
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Xagenic Provider of point-of-care molecular diagnostics for infectious diseases | $59M | 136 mo ago | Series C | 45 | — | 50 patents Electrochemical biosensor platforms with integrated reagent handling and precision bio‑electronics. | — |
| 2 | Radiant Biotherapeutics Developer of therapeutics for cancer, auto-immune and infectious diseases 37Patents top 33%Funding top 34%Moat top 38%Innovation top 40% All 9 signals ▾Patentstop 33% Fundingtop 34% Moattop 38% Innovationtop 40% Techtop 41% Growthbottom 47% Globalbottom 40% Marketbottom 26% Newsbottom 18% Patents: 38 patents matched (strict assignee match) · 38 filings since 2022 vs 0 in 2017-21 Funding: Raised $43.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $43M | 26 mo ago | Series A | 11 | — | 38 patents Multibody protein therapeutics targeting TNF receptors and multivalent cytokine modulation | — |
| 3 | Qvella Developer of a platform aimed to provide a more accurate and faster diagnosis of bacteria identification | $40M | 107 mo ago | Deadpooled | 101 | — | 85 patents Rapid microbial diagnostics: sample prep, cell separation, classification, and antibiotic susceptibility testing. | — |
| 4 | SQI Diagnostics Developer of multiplexed tests and automated systems for biological testing. | $37M | 47 mo ago | Public | 70 | — | 75 patents Multiplexed immunoassay microarray analysis and quantitative antibody‑binding optimization | — |
| 5 | Spectral Develops theranostic solutions for sepsis | $30M | 48 mo ago | Public | 32 | Chris Seto Chief Executive Officer | — | — |
| 6 | Revive Therapeutics Developer of therapeutics to treat rare and infectious diseases 27Product top 24%Moat top 32%Funding top 36%Patents top 42% All 10 signals ▾Producttop 24% Moattop 32% Fundingtop 36% Patentstop 42% Innovationtop 44% Growthtop 48% Techbottom 48% Newsbottom 43% Globalbottom 31% Marketbottom 16% Product: 2 distinct product lines · Company stage: Public Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $17M | 15 mo ago | Public | 3 | — | 24 patents Repurposed drug therapeutics for neuroprotection, stroke, migraines, and infectious diseases | — |
| 7 | Virica Biotech Developer of viral sensitizer technology therapeutics to treat viral infections | $12M | 30 mo ago | Series A | 29 | Jean Diallo Founder & CEO | 4 patents Enhancing viral vector production via kinase inhibitor modulation for gene therapy manufacturing | — |
| 8 | Chipcare Develops a hand-held blood test from a single drop of blood | $11M | 119 mo ago | Deadpooled | 10 | — | 24 patents Multiplex bead‑array immunoassays and optical cell‑detection microfluidic devices. | — |
| 9 | Fio Point-of-care digital diagnostic integrated with cloud information services for infectious diseases | $11M | 118 mo ago | Series B | 40 | Michael Greenberg Chairman and Chief Executive Officer | 189 patents Patents concentrated in computing, sensing & instrumentation | — |
| 10 | Lactiga Developer of immunotherapies to treat infectious diseases | $2M | 21 mo ago | Seed | 5 | Viraj Mane Co-Founder | 8 patents Polyclonal antibody therapeutics for RSV and oral delivery of pooled breastmilk antibodies | — |
| 11 | T.A.Z. Corporation Developer of small molecule for the treatment of antimicrobial resistant infections | $813K | 106 mo ago | Seed | — | Keith Micetich CEO | — | — |
| 12 | Ostia Sciences Developer of microbes for fighting infectious diseases and enhancing immune function | $740K | 15 mo ago | Seed | — | Michael Glogauer Co-Founder | — | — |
| 13 | StokedBio Developer of therapeutics based on AI technology 45Talent top 28%AI top 45%Funding top 46%Market bottom 37% All 5 signals ▾Talenttop 28% AItop 45% Fundingtop 46% Marketbottom 37% Globalbottom 29% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 45/100 | $366K | 6 mo ago | Seed | — | Chris Sinclair Co-Founder | — | — |
| 14 | Sairiyo Therapeutics Developer of therapeutic solutions for the treatment of rare diseases | $300K | 39 mo ago | Acqui-Hired | — | Paul Slyke Co-Founder & CSO | — | — |
Top 12 Infectious Diseases companies in Ontario
#1
Public · Toronto, Ontario · founded 2012 · 3 employees$16.8Mraised▾
Developer of therapeutics to treat rare and infectious diseases. Its lead product Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) helps in treating infectious diseases, including COVID-19, influenza, and others. Also has psilocybin for multiple indications.
- Aug 2025Post IPO$110.7K
- Apr 2025Post IPO$120.2K
- Jan 2024Post IPO$1.6M
- Jan 2023Post IPO$4.3M
#2
Seed · Hamilton, Ontario · founded 2024$365.5Kraised▾
Developer of therapeutics based on AI technology. It offers AI-based platform for molecular property prediction and molecular design for drug discovery for antibacterial, antifungal, antiviral, and cancer applications.
- May 2026Seed$365.5K
#3
Series A · Toronto, Ontario · founded 2020 · 11 employees$43Mraised▾
Developer of therapeutics for cancer, auto-immune and infectious diseases. It offers multi-valent, multi-specific antibody therapeutics based on antibody engineering platform that targets biological pathways to treat diverse diseases.
- Sep 2024Series A$35M
- Apr 2023Seed$8M
#4
Seed · Toronto, Ontario · founded 2020$739.9Kraised▾
Developer of microbes for fighting infectious diseases and enhancing immune function. The company offers Salivaricin 10 a phosphorylated antibiotic in the identification and development of beneficial microbes that play a crucial role in fighting infectious diseases and enhancing immune function.
- Jul 2025Grant (prize money)$393K
- Oct 2024Seed$1.1M
#5
Seed · Toronto, Ontario · founded 2017 · 5 employees$1.6Mraised▾
Developer of immunotherapies to treat infectious diseases. The company has developed a patented biologic called LCTG-001 to treat PID such as selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID).
- Feb 2025Grant (prize money)—
- Jan 2025Grant (prize money)$304.6K
- Sep 2022Seed$1.6M
- Sep 2022Grant (prize money)$350K
#6
Series A · Ottawa, Ontario · founded 2018 · 29 employees$11.6Mraised▾
Developer of viral sensitizer technology therapeutics to treat viral infections. The novel Viral Sensitizer technology consists of a library of small molecules (novel Viral Sensitizers) identified using a high-throughput screening process to target viral infections.
- Apr 2024Series A$60K
- Jan 2024Series A$3M
- Apr 2023Grant (prize money)$790K
- May 2022Series A$5M
#7
Public · Toronto, Ontario · founded 1999 · 70 employees$36.7Mraised▾
Developer of multiplexed tests and automated systems for biological testing. The company's proprietary Ig_plex technology provides laboratories and clinical research organizations with the ability to simultaneous, automated analyses of customized multiple biomarkers down to the isotype and subclass level. The products include RALI-dx COVID-19 severity triage tests, home testing kits, and lung inflammation diagnostic tests.
- Dec 2022Post IPO$744.8K
- Nov 2021Post IPO$489.6K
- Nov 2021Post IPO$3.6M
- Jun 2021Post IPO$3.9M
#8
Public · Toronto, Ontario · founded 1991 · 32 employees$30.2Mraised▾
Spectral is is a therapeutic development company focused on the development and commercialization of a product for the treatment of endotoxemic septic shock. The company's Endotoxin Activity Assay (EAA™), is the only FDA-cleared diagnostic test available to measure the risk of developing sepsis. PMX is a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. Its another product "Toraymyxin" (PMX) is a therapeutic hemoperfusion device that removes endotoxin, a key trigger of sepsis and septic shock, from the bloodstream. The device has beenapproved for therapeutic use in Japan and Europe. In addition, the company provides biochemicals including recombinant proteins, antibodies, and calibrators for research and commercial product.
- Nov 2022Post IPO$5M
- Apr 2018Post IPO$5.3M
- Mar 2016Post IPO$637.5K
- Jul 2014Post IPO$13.2M
#9
Series C · Toronto, Ontario · founded 2010 · 45 employees$59.1Mraised▾
Xagenic is developing a point-of-care platform for decentralized, rapid molecular diagnostic testing. The Xagenic X1 technology platform permits the rapid, enzyme-free detection of nucleic acids from clinical samples with automated proprietary Xagenic AuRA cartridges. The procedure involves the patient's clinical specimen to be introduced into the cartridge using a proprietary specimen collection kit and tube that snaps into the cartridge. Then, after the insertion of the cartridge into the Xagenic X1 instrument, all processes are fully automated. It is also developing assays for infectious diseases to be used with their platform.
- Jul 2015Series C$11.8M
- Jul 2014Series B$25.5M
- Dec 2013Series A$9.6M
- Jan 2012Series A$10M
#10
Deadpooled · Richmond Hill, Ontario · founded 2009 · 101 employees$39.7Mraised▾
Developer of a platform aimed to provide a more accurate and faster diagnosis of bacteria identification. The company offers sample preparation and detection technologies to clinical microbiology; Qvella's Field Activated Sample Treatment (FAST) technology utilizes a novel electrical lysing and sample treatment technique enabling rapid detection of infectious agents in a direct blood sample.
- Dec 2017Series B$19.7M
- Jun 2017Series A—
- Oct 2015Series A$20M
#11
Series B · Toronto, Ontario · founded 2006 · 40 employees$10.7Mraised▾
Point-of-care digital diagnostic integrated with cloud information services for infectious diseases. The company has developed a portable point-of-care device capable of molecular diagnosis of multiple infectious diseases from a small biological sample. Their product, Fionet, provides a point-of-care diagnosis for infectious disease. It works with mobile devices which automatically transmits primary data to a central web portal.
- Dec 2016Series B$8.3M
- Oct 2015Series A$75.7K
- Nov 2014Series A$100K
- Oct 2014Series A$704.8K
#12
Deadpooled · Toronto, Ontario · founded 2009 · 10 employees$11.1Mraised▾
ChipCare develops point of care blood testing platform for the health market. It has developed a handheld cell analyzer system that is used to test diseases from a single drop of blood sample. Its proprietary detection technique measures cell count, protein/enzyme and pathogen detection. The company offers a handheld reader and disposable test slide. First application is HIV.
- Nov 2016Series B$2.8M
- Mar 2015Series A$5M
- Sep 2013Seed$3.2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Diagnostics in Ontario is moving
A read on the academic research around Diagnostics in Ontario — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 47 papers.
- Ontario Institute for Cancer Research20
- Public Health Ontario12
- Children\'s Hospital of Eastern Ontario6
- Ontario Genomics4
- Ontario Medical Association2
- Liquid biopsy1→4
- Liquid biopsy3→6
- Cancer1→3
- Point-of-care testing4
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4
- Coronavirus disease 2019 (COVID-19)3
- Liquid biopsy3
- 2019-20 coronavirus outbreak2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.